Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparing the rate of immunotherapy treatment change due to toxicity by sex.
Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer EA. Chua KJ, et al. Among authors: tarhini aa. Cancer Rep (Hoboken). 2024 Feb;7(2):e1932. doi: 10.1002/cnr2.1932. Epub 2024 Jan 8. Cancer Rep (Hoboken). 2024. PMID: 38189893 Free PMC article.
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors.
Wheeler CE, Coleman SS 4th, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC. Wheeler CE, et al. Among authors: tarhini aa. bioRxiv [Preprint]. 2023 May 25:2023.05.24.542123. doi: 10.1101/2023.05.24.542123. bioRxiv. 2023. Update in: Cancer Res Commun. 2024 Aug 1;4(8):1978-1990. doi: 10.1158/2767-9764.CRC-23-0170. PMID: 37292921 Free PMC article. Updated. Preprint.
A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset.
Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS 4th, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q. Wang C, et al. Among authors: tarhini aa. bioRxiv [Preprint]. 2023 May 24:2023.05.24.541982. doi: 10.1101/2023.05.24.541982. bioRxiv. 2023. Update in: Cancer Res Commun. 2024 Feb 5;4(2):293-302. doi: 10.1158/2767-9764.CRC-23-0213. PMID: 37292990 Free PMC article. Updated. Preprint.
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
Tometich DB, Geiss C, Maconi ML, Chavez M, Hoogland AI, Li X, Nieves-Lopez A, Rodriguez Y, Bryant C, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Hwu P, Khushalani NI, Jim HSL. Tometich DB, et al. Among authors: tarhini aa. Support Care Cancer. 2024 May 6;32(6):330. doi: 10.1007/s00520-024-08538-8. Support Care Cancer. 2024. PMID: 38709312
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages.
Mandula JK, Sierra-Mondragon RA, Jimenez RV, Chang D, Mohamed E, Chang S, Vazquez-Martinez JA, Cao Y, Anadon CM, Lee SB, Das S, Rocha-Munguba L, Pham VM, Li R, Tarhini AA, Furqan M, Dalton W, Churchman M, Moran-Segura CM, Nguyen J, Perez B, Kojetin DJ, Obermayer A, Yu X, Chen A, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Mandula JK, et al. Among authors: tarhini aa. Immunity. 2024 May 14;57(5):1124-1140.e9. doi: 10.1016/j.immuni.2024.03.020. Epub 2024 Apr 17. Immunity. 2024. PMID: 38636522
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma.
Ramadoss T, Nichols M, Palacios C, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Khushalani NI, Tsai KY, Brohl AS. Ramadoss T, et al. Among authors: tarhini aa. J Immunother Cancer. 2024 Sep 5;12(9):e009816. doi: 10.1136/jitc-2024-009816. J Immunother Cancer. 2024. PMID: 39242118 Free PMC article.
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.
Wang X, Li T, Eljilany I, Sukrithan V, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Wang X, et al. Among authors: tarhini aa. medRxiv [Preprint]. 2024 Jul 21:2024.07.19.24310726. doi: 10.1101/2024.07.19.24310726. medRxiv. 2024. PMID: 39072034 Free PMC article. Preprint.
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Dravillas CE, Coleman SS 4th, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC; exORIEN Consortium. Dravillas CE, et al. Among authors: tarhini aa. Cancer Res Commun. 2024 Aug 1;4(8):1978-1990. doi: 10.1158/2767-9764.CRC-23-0170. Cancer Res Commun. 2024. PMID: 39015091 Free PMC article.
148 results